Leqvio Injection, Solution
Product Images NDC 0078-1000

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Leqvio (NDC 0078-1000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Formula Of Inclisiran Sodium (Leqvio 01)

Chemical structure diagram of inclisiran sodium showing the sense and antisense strands with nucleotide modifications. The image includes molecular structures of 2'-F and 2'-OMe nucleotides, thymidine (dT), phosphorothioate linkage (s), and the L96 conjugate moiety, illustrating the detailed chemical composition of the active ingredient inclisiran sodium.*

FDA Label Image

Figure 1: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 1) (Leqvio 02)

A line graph showing percent change from baseline in LDL cholesterol over 18 months comparing inclisiran and placebo. The graph includes two lines, one solid for inclisiran showing a significant decline and one dashed for placebo with little change. Patient numbers for each group are noted below the timeline for several time points.*

FDA Label Image

Figure 2: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 2) (Leqvio 03)

A line graph depicting percent change from baseline in LDL Cholesterol over 18 months. The x-axis represents months, while the y-axis shows percentage change. Two lines represent data for Placebo (dashed line) and Inclisiran (solid line), with the Inclisiran group showing a substantial decrease in LDL cholesterol. Patient numbers at various time points for Placebo and Inclisiran groups are listed below the graph as part of the ORION-11 study.*

FDA Label Image

Figure 3: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hefh On Maximally Tolerated Statin Therapy (study 3) (Leqvio 04)

Line chart showing percent change from baseline in LDL cholesterol over 18 months comparing inclisiran and placebo. The x-axis represents time in months, and the y-axis shows percent change, with inclisiran demonstrating a notable reduction while placebo remains near baseline. Patient numbers for each group are listed below the x-axis.*

FDA Label Image

Principal Display Panel Leqvio® (inclisiran) Injection Contains One Single-dose Prefilled Syringe For Subcutaneous Use For Administration By A Healthcare Professional Only 284 mg/1.5 mL (189 mg/ml) Ndc 0078-1000-60 Sterile Solution Rx Only Novartis (Leqvio 05)

Packaging label for LEQVIO (inclisiran) injection, 284 mg/1.5 mL (189 mg/mL) single-dose prefilled syringe for subcutaneous use. The label includes dosage, storage instructions, manufacturer Sandoz GmbH, Novartis Pharmaceuticals Corporation as distributor, and a barcode. The label highlights that the product is for administration by healthcare professionals only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.